



Missouri Pharmacy Program – Preferred Drug List



Cryopyrin-Associated Periodic Syndrome (CAPS) Agents

Effective 05/26/2010

Revised 10/04/2018

Preferred Agents

- Ilaris®

Non-Preferred Agents

- Arcalyst®

Approval Criteria

- Appropriate Diagnosis
 - Cryopyrin-associated periodic syndrome (CAPS)
 - Familial Cold Autoinflammatory Syndrome (FCAS)
 - Familial Cold Urticaria (FCU)
 - Muckle-Wells Syndrome (MWS)
 - Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
- Failure to achieve desired therapeutic outcomes with trial on 1 preferred agent
 - Documented trial period for preferred agents
 - Documented ADE/ADR to preferred agents
- Documented compliance on current therapy regimen

Denial Criteria

- Lack of approval criteria
- Lack of adequate trial on required preferred agents
- Patient less than 4 years old for Ilaris therapy
- Patients less than 12 years old for Arcalyst therapy
- Concurrent Tumor Necrosis Factor (TNF) blocking agent therapy
- Drug Prior Authorization Hotline: (800) 392-8030